News Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer Staff September 11, 2023 Post Views: 30 Related Continue Reading Previous EyePoint Pharmaceuticals Reports Positive Masked Safety Update for Lead Product Candidate EYP-1901 in Ongoing PAVIA and DAVIO 2 Phase 2 Clinical Trials as of September 1, 2023Next Plus Therapeutics Receives $1.9 Million Advance Payment from CPRIT and Plans to Present at the CPRIT Innovations in Cancer Prevention and Research Conference More Stories Healthcare News Nursing Patient Care Riverside University Health System to Implement FloPatch by Flosonics, Revolutionizing Precision Fluid Management in Sepsis Care Staff September 21, 2023 Healthcare News NuGen Medical Completes Delivery and First Sale of 500 InsuJet(TM) Devices and Consumables in Romania Staff September 20, 2023 News Izotropic Closes Non-Brokered Private Placement Staff September 20, 2023
